The effect of mobilisation of patients during treatment of thromboembolic disorders with low-molecular-weight heparin.
OBJECTIVE
To elucidate the risk of pulmonary embolism (PE) in patients with deep vein thrombosis (DVT) who are kept walking with compression bandages.


METHODS
Perfusion/ventilation scanning of the lungs was performed at admission and after 10 days of treatment.


METHODS
General community hospital.


METHODS
A total of 631 consecutive patients were studied (upper limit of the thrombi: iliofemoral vein, n=212; femoral or popliteal vein, n=302; lower leg, n=117). The patients received different dose regimens of low-molecular-weight heparin (dalteparin) subcutaneously.


RESULTS
The study revealed that the prevalence of PE at baseline was between 45.1% and 51% (95% CI 38.2-55.2 and 45.2-56.8% respectively) in patients with proximal DVT, and 31.9% (95% CI 23.6-41.2%) in those with DVT restricted to the lower leg. The majority of these cases of PE were completely asymptomatic. The incidence of a new PE, revealed by a second lung scan on day 10 after admission, was 7.0% (95% CI 3.9-11.4%) in patients with iliofemoral DVT, 5.5% (95% CI 3.2-8.7%) in those with femoropopliteal DVT and 2.7% (95% CI 0.6-7.6%) in those with lower-leg DVT. These incidence rates for new PEs were significantly lower than the rates previously reported (p<0.01). The fatality rate was also lower compared with the literature: one patient suffered a fatal PE (0.2%; 95% CI 0-0.9%), four patients died from malignant tumours, and one from pneumonia. The frequency of malignant tumours was greater in this study than in the literature (23% in patients with iliofemoral DVT, 14% in those with femoropopliteal DVT and 9% in those with DVT of the lower leg).


CONCLUSIONS
Mobile patients with DVT do not need bed-rest. Low-molecular-weight heparin s.c., compression bandages and walking exercises make home-treatment of DVT feasible.
Partsch
H
H
Department of Dermatology, Wilhelminenspital, Vienna, Austria.
Kechavarz
B
B
Köhn
H
H
Mostbeck
A
A
D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D001458:Bandages; D005260:Female; D005268:Femoral Vein; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D007084:Iliac Vein; D007103:Immobilization; D015994:Incidence; D007866:Leg / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D011152:Popliteal Vein; D011655:Pulmonary Embolism / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D012189:Retrospective Studies; D013923:Thromboembolism / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000150:complications / Q000628:therapy*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight